The Activity of the Lipophilic Nucleoside Derivatives Elacytarabine and CP-4126 in a Panel of Tumor Cell Lines Resistant to Nucleoside Analogues

REFERENCES

• Galmarini , C. M. , Mackey , J. R. and Dumontet , C. 2001 . Nucleoside analogues: mechanisms of drug resistance and reversal strategies . Leukemia , 15 : 875 – 890 .
   PubMed Web of Science ®Google Scholar
• Bergman , A. M. , Kuiper , C. M. , Noordhuis , P. , Smid , K. , Voorn , D. A. , Comijn , E. M. , Myhren , F. , Sandvold , M. L. , Hendriks , H. R. , Fodstad , O. , Breistol , K. and Peters , G. J. 2004 . Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts . Nucleosides Nucleotides Nucleic Acids , 23 : 1329 – 1333 .
   PubMed Web of Science ®Google Scholar
• Dueland , S. , Aamdal , S. , Lind , M. J. , Thomas , H. , Sandvold , M. L. , Gaullier , J. M. and Rasch , W. 2009 . Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. a phase I study . Acta Oncol , 48 : 137 – 145 .
   PubMed Web of Science ®Google Scholar
• Galmarini , C. M. , Myhren , F. and Sandvold , M. L. 2009 . CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines . Br. J. Haematol. , 144 : 273 – 275 .
   PubMed Web of Science ®Google Scholar
• Breistol , K. , Balzarini , J. , Sandvold , M. L. , Myhren , F. , Martinsen , M. , De Clercq , E. and Fodstad , O. 1999 . Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models . Cancer Res. , 59 : 2944 – 2949 .
   PubMed Web of Science ®Google Scholar
• Bergman , A. M. , Eijk , P. P. , Ruiz van Haperen , V. W. , Smid , K. , Veerman , G. , Hubeek , I. , van den Ijssel , P. , Ylstra , B. and Peters , G. J. 2005 . In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant . Cancer Res. , 65 : 9510 – 9516 .
   PubMed Web of Science ®Google Scholar
• Jordheim , L. P. , Guittet , O. , Lepoivre , M. , Galmarini , C. M. and Dumontet , C. 2005 . Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells . Mol. Cancer Ther. , 4 : 1268 – 1276 .
   PubMed Web of Science ®Google Scholar
• Beck , W. T. , Cirtain , M. C. and Lefko , J. L. 1983 . Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts . Mol. Pharmacol. , 24 : 485 – 492 .
   PubMed Web of Science ®Google Scholar
• Twentyman , P. R. , Fox , N. E. , Wright , K. A. and Bleehen , N. M. 1986 . Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells . Br. J. Cancer , 53 : 529 – 537 .
   PubMed Web of Science ®Google Scholar
• Adema , A. , Smid , K. , Losekoot , N. , Myhren , F. , Sandvold , M. L. and Peters , G. J. Fatty acid derivatives of cytarabine and gemcitabine, CP-4055 and CP-4126, show a prolonged cellular retention compared to the parent drug . Proceedings of the 99th Annual Meeting of the American Association for Cancer Research , Vol. Abstract nr 5740 ,
   Google Scholar
• Giovannetti , E. , Del Tacca , M. , Mey , V. , Funel , N. , Nannizzi , S. , Ricci , S. , Orlandini , C. , Boggi , U. , Campani , D. , Del Chiaro , M. , Iannopollo , M. , Bevilacqua , G. , Mosca , F. and Danesi , R. 2006 . Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine . Cancer Res. , 66 : 3928 – 3935 .
   PubMed Web of Science ®Google Scholar
• Marechal , R. , Mackey , J. R. , Lai , R. , Demetter , P. , Peeters , M. , Polus , M. , Cass , C. E. , Young , J. , Salmon , I. , Deviere , J. and Van Laethem , J. L. 2009 . Human Equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma . Clin. Cancer Res. , 15 : 2913 – 2919 .
   PubMed Web of Science ®Google Scholar
• Farrell , J. J. , Elsaleh , H. , Garcia , M. , Lai , R. , Ammar , A. , Regine , W. F. , Abrams , R. , Benson , A. B. , Macdonald , J. , Cass , C. E. , Dicker , A. F. and Mackey , J. R. 2009 . Human Equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer . Gastroenterology , 136 : 187 – 195 .
   PubMed Web of Science ®Google Scholar
• Hubeek , I. , Giovannetti , E. , Broekhuizen , A. J. , Pastor-Anglada , M. , Kaspers , G. J. and Peters , G. J. 2008 . Immunocytochemical detection of hENT1 and hCNT1 in normal tissues, lung cancer cell lines, and NSCLC patient samples . Nucleosides Nucleotides Nucleic Acids , 27 : 787 – 793 .
   PubMed Web of Science ®Google Scholar
• Oguri , T. , Achiwa , H. , Muramatsu , H. , Ozasa , H. , Sato , S. , Shimizu , S. , Yamazaki , H. , Eimoto , T. and Ueda , R. 2007 . The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer . Cancer Lett. , 256 : 112 – 119 .
   PubMed Web of Science ®Google Scholar
• Wiley , J. S. , Jones , S. P. , Sawyer , W. H. and Paterson , A. R. 1982 . Cytosine arabinoside influx and nucleoside transport sites in acute leukemia . J. Clin. Invest. , 69 : 479 – 489 .
   PubMed Web of Science ®Google Scholar
• Hubeek , I. , Stam , R. W. , Peters , G. J. , Broekhuizen , R. , Meijerink , J. P. , van Wering , E. R. , Gibson , B. E. , Creutzig , U. , Zwaan , C. M. , Cloos , J. , Kuik , D. J. , Pieters , R. and Kaspers , G. J. 2005 . The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia . Br. J. Cancer , 93 : 1388 – 1394 .
   PubMed Web of Science ®Google Scholar
• Martin , L. P. , Hamilton , T. C. and Schilder , R. J. 2008 . Platinum resistance: the role of DNA repair pathways . Clin. Cancer Res. , 14 : 1291 – 1295 .
   PubMed Web of Science ®Google Scholar
• Flanagan , S. A. , Robinson , B. W. , Krokosky , C. M. and Shewach , D. S. 2007 . Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: a new paradigm for antimetabolite radiosensitizers . Mol. Cancer Ther. , 6 : 1858 – 1868 .
   PubMed Web of Science ®Google Scholar
• Mao , G. , Yuan , F. , Absher , K. , Jennings , C. D. , Howard , D. S. , Jordan , C. T. and Gu , L. 2008 . Preferential loss of mismatch repair function in refractory and relapsed acute myeloid leukemia: potential contribution to AML progression . Cell Res. , 18 : 281 – 289 .
   PubMed Web of Science ®Google Scholar
• Peters , G. J. , Van Moorsel , C. J. , Lakerveld , B. , Smid , K. , Noordhuis , P. , Comijn , E. C. , Weaver , D. , Willey , J. C. , Voorn , D. , Van der Vijgh , W. J. and Pinedo , H. M. 2006 . Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines . Int. J. Oncol. , 28 : 237 – 244 .
   PubMed Web of Science ®Google Scholar
• Dong , X. , Jiao , L. , Li , Y. , Evans , D. B. , Wang , H. , Hess , K. R. , Abbruzzese , J. L. and Li , D. 2009 . Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer . J. Clin. Oncol. , 27 : 1592 – 1599 .
   PubMed Web of Science ®Google Scholar